Affimed NV (NASDAQ:AFMD) shares fell 6.2% during mid-day trading on Wednesday . The company traded as low as $5.00 and last traded at $5.25. 2,125,523 shares traded hands during mid-day trading, an increase of 108% from the average session volume of 1,020,211 shares. The stock had previously closed at $5.60.
A number of brokerages have issued reports on AFMD. ValuEngine upgraded Affimed from a “sell” rating to a “hold” rating in a research note on Friday, June 1st. BMO Capital Markets reduced their price objective on Affimed from $6.00 to $4.00 and set an “outperform” rating for the company in a research note on Thursday, August 9th. Zacks Investment Research downgraded Affimed from a “hold” rating to a “sell” rating in a research note on Tuesday, May 22nd. BidaskClub upgraded Affimed from a “strong sell” rating to a “sell” rating in a research note on Friday, August 31st. Finally, Jefferies Financial Group upgraded Affimed from a “hold” rating to a “buy” rating and increased their price target for the stock from $1.80 to $4.00 in a research note on Tuesday, August 28th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Affimed presently has a consensus rating of “Buy” and a consensus target price of $3.75.
The company has a quick ratio of 5.33, a current ratio of 5.36 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $327.55 million, a price-to-earnings ratio of -6.47 and a beta of 3.53.
Hedge funds have recently bought and sold shares of the company. Eversept Partners LLC bought a new position in shares of Affimed during the 1st quarter worth $716,000. Dimensional Fund Advisors LP grew its stake in shares of Affimed by 28.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 319,871 shares of the biopharmaceutical company’s stock worth $592,000 after acquiring an additional 71,545 shares during the period. Millennium Management LLC bought a new position in shares of Affimed during the 1st quarter worth $4,731,000. CVI Holdings LLC bought a new position in shares of Affimed during the 1st quarter worth $667,000. Finally, Sofinnova Ventures Inc bought a new position in shares of Affimed during the 1st quarter worth $205,000. Institutional investors own 41.11% of the company’s stock.
Affimed Company Profile (NASDAQ:AFMD)
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.
Featured Story: Diversification Important in Investing
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.